FIVE PRIME THERAPEUTICS INC's ticker is FPRX and the CUSIP is 33830X104. A total of 128 filers reported holding FIVE PRIME THERAPEUTICS INC in Q3 2017. The put-call ratio across all filers is 0.69 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2021 | $645,000 | +125.5% | 17,112 | +1.8% | 0.27% | +128.6% |
| Q4 2020 | $286,000 | -22.3% | 16,810 | -38.9% | 0.12% | -84.8% |
| Q1 2019 | $368,000 | +26.0% | 27,492 | -12.5% | 0.78% | +1466.0% |
| Q4 2018 | $292,000 | -21.7% | 31,427 | +17.2% | 0.05% | +28.2% |
| Q3 2018 | $373,000 | -48.7% | 26,824 | -41.7% | 0.04% | -93.9% |
| Q2 2018 | $727,000 | +17.1% | 46,007 | +27.3% | 0.64% | +19.3% |
| Q1 2018 | $621,000 | +63.0% | 36,128 | +108.0% | 0.54% | +12.8% |
| Q4 2017 | $381,000 | -15.1% | 17,371 | +58.4% | 0.48% | +683.6% |
| Q3 2017 | $449,000 | +49.7% | 10,966 | +10.1% | 0.06% | +35.6% |
| Q2 2017 | $300,000 | +47.8% | 9,963 | +77.0% | 0.04% | +25.0% |
| Q1 2017 | $203,000 | -20.4% | 5,628 | +10.6% | 0.04% | -52.6% |
| Q4 2016 | $255,000 | -16.7% | 5,088 | -12.8% | 0.08% | -48.6% |
| Q3 2016 | $306,000 | +27.0% | 5,837 | 0.0% | 0.15% | -17.3% |
| Q2 2016 | $241,000 | -6.2% | 5,837 | -7.7% | 0.18% | -49.4% |
| Q1 2016 | $257,000 | – | 6,321 | – | 0.35% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 115,500 | $2,531,000 | 0.89% |
| AWM Investment Company, Inc. | 150,000 | $3,288,000 | 0.64% |
| BB BIOTECH AG | 827,500 | $18,139,000 | 0.51% |
| Virtus ETF Advisers LLC | 17,371 | $381,000 | 0.48% |
| Rock Springs Capital Management LP | 425,000 | $9,316,000 | 0.42% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 450,728 | $9,880,000 | 0.39% |
| Telemetry Investments, L.L.C. | 44,176 | $968,000 | 0.37% |
| RTW INVESTMENTS, LP | 100,377 | $2,200,000 | 0.37% |
| Eventide Asset Management | 315,000 | $6,905,000 | 0.36% |
| ACUTA CAPITAL PARTNERS, LLC | 52,500 | $1,151,000 | 0.22% |